Galantamine Improves Motor and Sensory Dysfunction in Patients With Acute Ischemic Stroke

Launched by SHANGHAI YUEYANG INTEGRATED MEDICINE HOSPITAL · May 26, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called galantamine to see if it can help improve movement and sensation in patients who have recently had an acute ischemic stroke, which is caused by a blockage in the blood vessels of the brain. While current treatments can reopen these blocked vessels, many patients still experience significant difficulties afterward. The researchers believe that galantamine may help by improving blood flow in the brain and protecting it from further damage.

To participate in this trial, you need to be diagnosed with an acute ischemic stroke within 72 hours of your symptoms starting and have a specific level of stroke severity. Additionally, you should generally be in good health before the stroke. Participants will receive either galantamine or standard treatment to see how well it works. This trial is not yet recruiting, so it’s important to stay connected with your healthcare provider for updates. If you join, you'll help researchers learn more about potential new treatments that could benefit many stroke patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of acute ischemic stroke within 72h of symptom onset
• • A score of 4-25 points on the National Institute of Health Stroke Scale (NIHSS)
• • The mRS score before stroke is 0-1
• • Patient and family members sign informed consent
• Exclusion Criteria:
• • Cranial imaging examinations confirm the presence of diseases causing similar symptoms such as brain tumors, encephalitis, brain abscess, etc., or confirm hemorrhagic cerebral infarction, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc
• • Patients with active bleeding or bleeding tendency, malignancies, severe liver (the serum level of AST and/or ALT \> 2 times the upper limit of normal), or renal failure (the serum level of creatinine \> 1.5 times the upper limit of normal or GFR \< 40 ml/min/1.73m2)
• • Elderly people with weak constitutions or patients complicated with infections
• • Patients with a history of mental illness or severe dementia
• • A significant history of drug or alcohol abuse
• • Allergic constitution, or allergic to two or more drugs or foods
• • Pregnancy, lactation, or planning to get pregnant
• • Patients who are currently participating in or have participated in other clinical trials within the past 1 month
• • Currently using or having used other cholinesterase inhibitor drugs within the past 3 months
• • Having taken galantamine within 1 month before randomization, or being required to take galantamine for other diseases within the next 90 days
• • Patients with epilepsy, hyperkinesia, mechanical intestinal obstruction, bronchial asthma, angina pectoris, bradycardia, or glaucoma
• • Individuals with contraindications to MRI examination
• • Individuals who are allergic to the ingredients of the administered drug